Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C
Open Access
- 18 September 2012
- journal article
- viral hepatitis
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 57 (3), 964-973
- https://doi.org/10.1002/hep.26087
Abstract
The aim of this retrospective cohort study was to assess the cumulative development incidence and predictive factors for malignancies after the termination of interferon (IFN) therapy in Japanese patients for hepatitis C virus (HCV). A total of 4,302 HCV-positive patients treated with IFN were enrolled. The mean observation period was 8.1 years. The primary outcome was the first onset of malignancies. Evaluation was performed using the Kaplan-Meier method and Cox proportional hazard analysis. A total of 606 patients developed malignancies: 393 developed hepatocellular carcinoma (HCC) and 213 developed malignancies other than HCC. The cumulative development rate of HCC was 4.3% at 5 years, 10.5% at 10 years, and 19.7% at 15 years. HCC occurred significantly (P < 0.05) when the following characteristics were present: advanced histological staging, sustained virological response not achieved, male sex, advanced age of ≥50 years, total alcohol intake of ≥200 kg, and presence of type 2 diabetes (T2DM). T2DM caused a 1.73-fold enhancement in HCC development. In patients with T2DM, HCC decreased when patients had a mean hemoglobin A1c (HbA1c) level of P = 0.015). The cumulative development rate of malignancy other than HCC was 2.4% at 5 years, 5.1% at 10 years, and 9.8% at 15 years. Malignancies other than HCC occurred significantly when patients were of advanced age of ≤50 years, smoking index (package per day × year) was ≥ 20, and T2DM was present. T2DM caused a 1.70-fold enhancement in the development of malignancies other than HCC. Conclusion: T2DM causes an approximately 1.7-fold enhancement in the development of HCC and malignancies other than HCC in HCV-positive patients treated with IFN. In T2DM patients, maintaining a mean HbA1c level of <7.0% reduces the development of HCC. (HEPATOLOGY 2013)Keywords
Funding Information
- Japanese Ministry of Health, Labour and Welfare
This publication has 44 references indexed in Scilit:
- Differential expression of anterior gradient gene AGR2 in prostate cancerBMC Cancer, 2010
- Cancer Incidence and Incidence Rates in Japan in 2005: Based on Data from 12 Population-based Cancer Registries in the Monitoring of Cancer Incidence in Japan (MCIJ) ProjectJapanese Journal of Clinical Oncology, 2010
- Diagnosis and Classification of Diabetes MellitusDiabetes Care, 2010
- The LKB1–AMPK pathway: metabolism and growth control in tumour suppressionNature Reviews Cancer, 2009
- Smoking and Colorectal CancerJAMA, 2008
- Diabetes and Risk of Non-Hodgkin's LymphomaDiabetes Care, 2008
- Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis CHepatology, 2008
- Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus‐infected and hepatitis C virus‐cleared patientsLiver International, 2008
- Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. AdultsNew England Journal of Medicine, 2003
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958